Baricitinib

Phase 3Recruiting

1 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Juvenile Idiopathic Arthritis

Conditions

Juvenile Idiopathic Arthritis

Trial Timeline

Apr 5, 2019 → Jul 1, 2031

NCT ID

NCT03773965

About Baricitinib

Baricitinib is a phase 3 stage product being developed by Eli Lilly for Juvenile Idiopathic Arthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03773965. Target conditions include Juvenile Idiopathic Arthritis.

What happened to similar drugs?

0 of 20 similar drugs in Juvenile Idiopathic Arthritis were approved

Approved (0) Terminated (2) Active (18)

🔄PLX-200 + PlaceboPolaryx TherapeuticsPhase 3

🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3

🔄MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3

🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3

🔄AdalimumabEisaiPhase 3

🔄AbataceptOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01724580	Pre-clinical	Completed	—	—	Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
NCT06797310	Phase 2	Recruiting	Jan 23, 2025	Dec 31, 2026	Alopecia Areata
NCT05074420	Phase 3	Terminated	Dec 21, 2021	Nov 4, 2024	Covid19
NCT04517253	Phase 2/3	Terminated	Oct 27, 2020	Nov 28, 2024	Nakajo-Nishimura Syndrome
NCT03921554	Phase 2	Completed	Jun 3, 2019	Mar 25, 2024	Aicardi Goutieres Syndrome
NCT03773965	Phase 3	Recruiting	Apr 5, 2019	Jul 1, 2031	Juvenile Idiopathic Arthritis
NCT03559270	Phase 3	Terminated	Jun 27, 2018	Jun 13, 2022	Atopic Dermatitis
NCT03026504	Phase 2	Completed	Mar 9, 2017	Apr 12, 2021	Arteritis, Giant Cell
NCT02263911	Phase 1	Completed	Nov 1, 2014	Dec 1, 2014	Healthy Participants
NCT01870388	Phase 1	Completed	Jun 1, 2013	Jul 1, 2013	Liver Diseases

Competing Products

20 competing products in Juvenile Idiopathic Arthritis

See all competitors

Product	Company	Stage	Hype Score
PLX-200 + Placebo	Polaryx Therapeutics	Phase 3	37
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
Adalimumab	Eisai	Phase 3	40
Abatacept	Ono Pharmaceutical	Phase 3	40
Ixekizumab + Adalimumab	Eli Lilly	Phase 3	44
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Tocilizumab	Eli Lilly	Phase 3	47
adalimumab + Methotrexate	AbbVie	Pre-clinical	26
Upadacitinib	AbbVie	Phase 1	33
Upadacitinib + Tocilizumab	AbbVie	Phase 3	47
Adalimumab + Risankizumab	AbbVie	Phase 3	47
Adalimumab	AbbVie	Phase 3	40
naproxen + esomeprazole	AstraZeneca	Phase 1	29
Alendronate (Fosamax)	Merck	Pre-clinical	26
canakinumab	Novartis	Phase 3	40
Secukinumab	Novartis	Phase 1	36
ACZ885 150 mg (Canakinumab)	Novartis	Phase 3	40